Ignite Creation Date:
2024-05-06 @ 3:44 PM
Last Modification Date:
2024-10-26 @ 1:56 PM
Study NCT ID:
NCT04749173
Status:
COMPLETED
Last Update Posted:
2021-12-13
First Post:
2021-01-20
Brief Title:
To Assess the Safety Tolerability and Pharmacokinetic Properties of Niclosamide Injectable DWRX2003 Which is the Treatment of COVID-19 in Healthy Volunteers
Sponsor:
Daewoong Pharmaceutical Co LTD
Organization:
Daewoong Pharmaceutical Co LTD
Study Overview
Official Title:
A Double-blind Randomized Placebo-controlled Single-ascending Dose Phase I Study to Evaluate the Safety Tolerability and Pharmacokinetic Properties of Niclosamide Injectable DWRX2003 Following Intramuscular Administration in Healthy Volunteers
Status:
COMPLETED
Status Verified Date:
2021-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This Phase I study is a double-blind randomized placebo-controlled study designed to assess the safety tolerability and PK profile of single intramuscular doses of DWRX2003 in healthy volunteers
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None